Please login to the form below

Not currently logged in
Email:
Password:

Indian generic drug firm expands in Russia

India-based Dr Reddy's Laboratories is to acquire the pharmaceutical prescription portfolio of JB Chemicals & Pharmaceuticals in Russia and other CIS nations

India-based Dr Reddy's Laboratories is to acquire the pharmaceutical prescription portfolio of JB Chemicals & Pharmaceuticals in Russia and other CIS nations.

Dr Reddy's will pay $34.85m to acquire the marketing licences for 20 brands, including Metrogyl (metronidazole) for infections and antihistamine Jocet (cetirizine).

Dr Reddy's has also entered into a supply agreement with JB Chemicals for the continued manufacturing and supply of these products associated with the acquired brands.

"Russia is one of our leading markets where we enjoy a strong equity with stakeholders," said Satish Reddy, MD of Dr Reddy's. "This acquisition will help expand our prescription, hospital and OTC portfolio, complement our existing strong basket of products and add to our growth aspirations in the Russia and other CIS region."

Related links

Find out more about the importance of Russia as a market for the pharmaceutical industry at
Russia: The inside story - the first of PMGroup's Country Report Live events.

 

25th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics